Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.

MLA

Herpers, Bram, et al. “Functional Patient-Derived Organoid Screenings Identify MCLA-158 as a Therapeutic EGFR × LGR5 Bispecific Antibody with Efficacy in Epithelial Tumors.” Nature Cancer, vol. 3, no. 4, Apr. 2022, pp. 418–36. EBSCOhost, https://doi.org/10.1038/s43018-022-00359-0.

APA

Herpers, B., Eppink, B., James, M. I., Cortina, C., Cañellas-Socias, A., Boj, S. F., Hernando-Momblona, X., Glodzik, D., Roovers, R. C., van de Wetering, M., Bartelink-Clements, C., Zondag-van der Zande, V., Mateos, J. G., Yan, K., Salinaro, L., Basmeleh, A., Fatrai, S., Maussang, D., Lammerts van Bueren, J. J., … Throsby, M. (2022). Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nature Cancer, 3(4), 418–436. https://doi.org/10.1038/s43018-022-00359-0

Chicago

Herpers, Bram, Berina Eppink, Mark I James, Carme Cortina, Adrià Cañellas-Socias, Sylvia F Boj, Xavier Hernando-Momblona, et al. 2022. “Functional Patient-Derived Organoid Screenings Identify MCLA-158 as a Therapeutic EGFR × LGR5 Bispecific Antibody with Efficacy in Epithelial Tumors.” Nature Cancer 3 (4): 418–36. doi:10.1038/s43018-022-00359-0.